Literature DB >> 3038316

Tamoxifen therapy in unresectable adenocarcinoma of the pancreas.

A Wong, A Chan, K Arthur.   

Abstract

Twenty-four patients with biopsy-documented unresectable ductal adenocarcinoma of the pancreas were treated with tamoxifen. Six of 15 postmenopausal female patients had documented prolonged survival, with three living greater than 2 years.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3038316

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  10 in total

Review 1.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Prognosis of common cancers.

Authors:  P H Geggie
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

3.  Effects of sex steroid hormones on pancreatic cancer in the rat.

Authors:  D S Longnecker; C Sumi
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

4.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 5.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 6.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

7.  A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Kai Siang Chan; Bernard Chi Shern Ho; Vishal G Shelat
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

8.  Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.

Authors:  Sanjay Singh Negi; Anil Agarwal; Adarsh Chaudhary
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

9.  A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.

Authors:  J J Keating; P J Johnson; A M Cochrane; B G Gazzard; N Krasner; P M Smith; P N Trewby; P Wheeler; S P Wilkinson; R Williams
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

10.  R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.

Authors:  Tomer Boldes; Keren Merenbakh-Lamin; Shani Journo; Eliya Shachar; Doron Lipson; Adva Yeheskel; Metsada Pasmanik-Chor; Tami Rubinek; Ido Wolf
Journal:  BMC Cancer       Date:  2020-06-08       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.